A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens

Cancer Metastasis: A Reappraisal of Its Underlying Mechanisms and Their Relevance to Treatment

(2018) Nicolo Riggi et al.   Annual Review of Pathology-Mechanisms of Disease

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cost Effectiveness of Gene Expression Profile Testing in Community Practice

(2018) Young Chandler et al.   JOURNAL OF CLINICAL ONCOLOGY

Functional Isolation of Tumor-Initiating Cells using Microfluidic-Based Migration Identifies Phosphatidylserine Decarboxylase as a Key Regulator

(2018) Yu-Chih Chen et al.   Scientific Reports

E-selectin-mediated rolling facilitates pancreatic cancer cell adhesion to hyaluronic acid

(2017) Daniel J. Shea et al.   FASEB JOURNAL

Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers

(2017) W Song et al.   ONCOGENE

Patient-derived xenograft (PDX) models in basic and translational breast cancer research

(2016) Lacey E. Dobrolecki et al.   CANCER AND METASTASIS REVIEWS

A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response

(2016) George Sflomos et al.   CANCER CELL

Interplay of the physical microenvironment, contact guidance, and intracellular signaling in cell decision making

(2016) Colin D. Paul et al.   FASEB JOURNAL

Time-lapse lens-free imaging of cell migration in diverse physical microenvironments

(2016) Evelien Mathieu et al.   LAB ON A CHIP

Nuclear constriction segregates mobile nuclear proteins away from chromatin

(2016) Jerome Irianto et al.   MOLECULAR BIOLOGY OF THE CELL

Cathepsin-B-mediated cleavage of Disabled-2 regulates TGF-β-induced autophagy

(2016) Yong Jiang et al.   NATURE CELL BIOLOGY

Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer

(2016) Roman Camarda et al.   NATURE MEDICINE

DEGRO practical guidelines for radiotherapy of breast cancer VI: therapy of locoregional breast cancer recurrences

(2016) Wolfgang Harms et al.   STRAHLENTHERAPIE UND ONKOLOGIE

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy

(2016) C. Alix-Panabieres et al.   Cancer Discovery

Ki-67 is required for maintenance of cancer stem cells but not cell proliferation

(2016) Justin Cidado et al.   Oncotarget

A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment

(2015) Denes Csonka et al.   JOURNAL OF CLINICAL PHARMACOLOGY

HISAT: a fast spliced aligner with low memory requirements

(2015) Daehwan Kim et al.   NATURE METHODS

PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling

(2015) H Cheng et al.   ONCOGENE

HER2missense mutations have distinct effects on oncogenic signaling and migration

(2015) Daniel J. Zabransky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

(2015) Isaac Garcia-Murillas et al.   Science Translational Medicine

Rad51 supports triple negative breast cancer metastasis.

(2015) Adrian P. Wiegmans et al.   Oncotarget

HTSeq--a Python framework to work with high-throughput sequencing data

(2014) S. Anders et al.   BIOINFORMATICS

Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours

(2014) Cathrine Leonowens et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

(2014) A. Prat et al.   CLINICAL CANCER RESEARCH

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

(2014) P. L. Bedard et al.   CLINICAL CANCER RESEARCH

The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor

(2013) Sara Koenig McLaughlin et al.   CANCER CELL

Circulating Tumor DNA — Ready for Prime Time?

(2013) Marc Lippman et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

(2013) H. Ebi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells

(2012) D. J. Mulholland et al.   CANCER RESEARCH

Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis

(2012) Matthew R. Dallas et al.   FASEB JOURNAL

Chemotaxis of Cell Populations through Confined Spaces at Single-Cell Resolution

(2012) ZiQiu Tong et al.   PLoS One

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

(2011) Yoko S DeRose et al.   NATURE MEDICINE

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

(2009) K. P. Hoeflich et al.   CLINICAL CANCER RESEARCH

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality

(2009) Elena López-Knowles et al.   INTERNATIONAL JOURNAL OF CANCER

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

(2009) Da Wei Huang et al.   Nature Protocols

Collagen-based cell migration models in vitro and in vivo

(2009) Katarina Wolf et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

(2008) Da Wei Huang et al.   NUCLEIC ACIDS RESEARCH